Logo image of URGN

UROGEN PHARMA LTD (URGN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:URGN - IL0011407140 - Common Stock

24.35 USD
-0.03 (-0.12%)
Last: 12/3/2025, 5:24:39 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to URGN. URGN was compared to 534 industry peers in the Biotechnology industry. URGN has a bad profitability rating. Also its financial health evaluation is rather negative. URGN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year URGN has reported negative net income.
URGN had a negative operating cash flow in the past year.
URGN had negative earnings in each of the past 5 years.
URGN had a negative operating cash flow in each of the past 5 years.
URGN Yearly Net Income VS EBIT VS OCF VS FCFURGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of URGN (-88.97%) is worse than 71.16% of its industry peers.
Industry RankSector Rank
ROA -88.97%
ROE N/A
ROIC N/A
ROA(3y)-60.9%
ROA(5y)-76.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
URGN Yearly ROA, ROE, ROICURGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K

1.3 Margins

Looking at the Gross Margin, with a value of 87.95%, URGN belongs to the top of the industry, outperforming 89.33% of the companies in the same industry.
In the last couple of years the Gross Margin of URGN has declined.
The Profit Margin and Operating Margin are not available for URGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.95%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.33%
GM growth 5Y-2.05%
URGN Yearly Profit, Operating, Gross MarginsURGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K -400K -500K

More info and screens

3

2. Health

2.1 Basic Checks

URGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for URGN has been increased compared to 1 year ago.
The number of shares outstanding for URGN has been increased compared to 5 years ago.
Compared to 1 year ago, URGN has an improved debt to assets ratio.
URGN Yearly Shares OutstandingURGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
URGN Yearly Total Debt VS Total AssetsURGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -5.82, we must say that URGN is in the distress zone and has some risk of bankruptcy.
URGN has a Altman-Z score of -5.82. This is in the lower half of the industry: URGN underperforms 63.86% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.82
ROIC/WACCN/A
WACC8.2%
URGN Yearly LT Debt VS Equity VS FCFURGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

2.3 Liquidity

A Current Ratio of 3.99 indicates that URGN has no problem at all paying its short term obligations.
URGN has a Current ratio (3.99) which is in line with its industry peers.
A Quick Ratio of 3.79 indicates that URGN has no problem at all paying its short term obligations.
URGN has a Quick ratio of 3.79. This is comparable to the rest of the industry: URGN outperforms 48.88% of its industry peers.
Industry RankSector Rank
Current Ratio 3.99
Quick Ratio 3.79
URGN Yearly Current Assets VS Current LiabilitesURGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for URGN have decreased by -9.84% in the last year.
URGN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.00%.
The Revenue has been growing by 438.30% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-9.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.45%
Revenue 1Y (TTM)8%
Revenue growth 3Y23.46%
Revenue growth 5Y438.3%
Sales Q2Q%9.04%

3.2 Future

Based on estimates for the next years, URGN will show a very strong growth in Earnings Per Share. The EPS will grow by 28.93% on average per year.
URGN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 52.19% yearly.
EPS Next Y-0.34%
EPS Next 2Y31.39%
EPS Next 3Y34.52%
EPS Next 5Y28.93%
Revenue Next Year31.55%
Revenue Next 2Y69.28%
Revenue Next 3Y65.7%
Revenue Next 5Y52.19%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
URGN Yearly Revenue VS EstimatesURGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
URGN Yearly EPS VS EstimatesURGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

URGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for URGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
URGN Price Earnings VS Forward Price EarningsURGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
URGN Per share dataURGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

URGN's earnings are expected to grow with 34.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.39%
EPS Next 3Y34.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for URGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UROGEN PHARMA LTD

NASDAQ:URGN (12/3/2025, 5:24:39 PM)

24.35

-0.03 (-0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-09 2026-03-09/amc
Inst Owners95.57%
Inst Owner Change6.15%
Ins Owners2.09%
Ins Owner Change0.04%
Market Cap1.14B
Revenue(TTM)96.52M
Net Income(TTM)-164.64M
Analysts84.29
Price Target35.96 (47.68%)
Short Float %20.9%
Short Ratio7.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.58%
Min EPS beat(2)-23.47%
Max EPS beat(2)2.31%
EPS beat(4)1
Avg EPS beat(4)-10.71%
Min EPS beat(4)-23.47%
Max EPS beat(4)2.31%
EPS beat(8)2
Avg EPS beat(8)-3.71%
EPS beat(12)5
Avg EPS beat(12)-0.39%
EPS beat(16)8
Avg EPS beat(16)0.67%
Revenue beat(2)1
Avg Revenue beat(2)-7.98%
Min Revenue beat(2)-18.58%
Max Revenue beat(2)2.61%
Revenue beat(4)1
Avg Revenue beat(4)-8.74%
Min Revenue beat(4)-18.58%
Max Revenue beat(4)2.61%
Revenue beat(8)3
Avg Revenue beat(8)-6.89%
Revenue beat(12)5
Avg Revenue beat(12)-4.68%
Revenue beat(16)5
Avg Revenue beat(16)-6.23%
PT rev (1m)4.44%
PT rev (3m)12.16%
EPS NQ rev (1m)2.28%
EPS NQ rev (3m)1.82%
EPS NY rev (1m)-0.79%
EPS NY rev (3m)-12.39%
Revenue NQ rev (1m)-3.04%
Revenue NQ rev (3m)-6.97%
Revenue NY rev (1m)-0.98%
Revenue NY rev (3m)-0.39%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.81
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.46
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)-2.95
FCFYN/A
OCF(TTM)-2.94
OCFYN/A
SpS2.06
BVpS-2.47
TBVpS-2.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -88.97%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.95%
FCFM N/A
ROA(3y)-60.9%
ROA(5y)-76.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.33%
GM growth 5Y-2.05%
F-Score2
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -121.32%
Cap/Sales 0.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.99
Quick Ratio 3.79
Altman-Z -5.82
F-Score2
WACC8.2%
ROIC/WACCN/A
Cap/Depr(3y)47.01%
Cap/Depr(5y)104.37%
Cap/Sales(3y)0.32%
Cap/Sales(5y)2.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.45%
EPS Next Y-0.34%
EPS Next 2Y31.39%
EPS Next 3Y34.52%
EPS Next 5Y28.93%
Revenue 1Y (TTM)8%
Revenue growth 3Y23.46%
Revenue growth 5Y438.3%
Sales Q2Q%9.04%
Revenue Next Year31.55%
Revenue Next 2Y69.28%
Revenue Next 3Y65.7%
Revenue Next 5Y52.19%
EBIT growth 1Y-59.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.28%
EBIT Next 3Y30.87%
EBIT Next 5YN/A
FCF growth 1Y-61.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.8%
OCF growth 3YN/A
OCF growth 5YN/A

UROGEN PHARMA LTD / URGN FAQ

What is the fundamental rating for URGN stock?

ChartMill assigns a fundamental rating of 3 / 10 to URGN.


What is the valuation status for URGN stock?

ChartMill assigns a valuation rating of 1 / 10 to UROGEN PHARMA LTD (URGN). This can be considered as Overvalued.


Can you provide the profitability details for UROGEN PHARMA LTD?

UROGEN PHARMA LTD (URGN) has a profitability rating of 1 / 10.


How financially healthy is UROGEN PHARMA LTD?

The financial health rating of UROGEN PHARMA LTD (URGN) is 3 / 10.